Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.0090 USD
Change Today 0.00 / 0.00%
Volume 80.4K
BIEI On Other Exchanges
As of 12:09 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

premier biomedical inc (BIEI) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/29/14 - $0.33
52 Week Low
10/6/15 - $0.0060
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

premier biomedical inc (BIEI) Related Businessweek News

No Related Businessweek News Found

premier biomedical inc (BIEI) Details

Premier Biomedical, Inc., a research-based company, discovers and develops medical treatments for various health issues. The company develops Sequential-Dialysis Technique, a methodology for the removal of molecules that are harmful and responsible for causing diseases, such as cancer, muscular dystrophy, neurofibromatosis, Ebola, etc., as well as to prevent the onset of various diseases; and Feldetrex drug candidate for the treatment of fibromyalgia and neuropathy. The company intends to market its products to pharmaceutical and/or medical devices firms. Premier Biomedical, Inc. has a collaborative agreement with the University of Texas to develop a series of research and development programs for its sequential-dialysis technology in the areas of cancer, chronic pain syndrome, fibromyalgia, multiple sclerosis, amyotrophic lateral sclerosis, blood sepsis, heart attacks, and strokes. The company was founded in 2010 and is based in El Paso, Texas.

premier biomedical inc (BIEI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: --
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

premier biomedical inc (BIEI) Key Developments

Premier Biomedical, Inc. Announces the Addition of Dr. Carl E. Meyer and Dr. Kathryn R. Meyer to Scientific Advisory Board

Premier Biomedical, Inc. announced the addition of Dr. Carl E. Meyer and his wife, Dr. Kathryn R. Meyer to their Scientific Advisory Board effective immediately. Dr. & Dr. Meyer will report to the co-founder and Chairman of the Scientific Advisory Board, Dr. Mitchell S. Felder, MD, and to the President and CEO, William A. Hartman. Carl E. Meyer, DO, MBA, is a pediatrician and a Fellow of the American Academy of Pediatrics. He has been a practicing pediatrician for 35 years, initially in solo practice in Greenville, PA, and currently with Hope Pediatrics in Seneca, PA. Dr. Carl Meyer spent many years on staff at University of Pennsylvania Medical Center (UPMC) Horizon as a general pediatrician, Chair of the Department of Pediatrics, and President of the Medical Staff. Kathryn Meyer, DO, is an Emergency Physician, certified by the American Academy of Osteopathic Emergency Physicians. She is currently Medical Director of the University of Pennsylvania Medical Center (UPMC) Hermitage Urgent Care Center in Hermitage, PA. Prior to that, she practiced Emergency Medicine at UPMC Horizon for 30 years.

Premier Biomedical, Inc. Files Patent Application on Cockayne Syndrome Treatment

Premier Biomedical, Inc. announced that they have filed an application with the U.S. Patent Office on a novel approach to the treatment of Cockayne Syndrome. Cockayne Syndrome (CS) is a rare and devastating neurodegenerative disorder characterized by slow growth, premature aging (progeria), shortened lifespan, moderately to severely inhibited neurological development, hearing loss, eye abnormalities/blindness, and sensitivity to sunlight. Cockayne Syndrome is caused by an inherited gene mutation.

Premier Biomedical, Inc. Announces Resignation of Justin Felder as the Member of Board of Directors

Premier Biomedical, Inc. announced that on August 18, 2015, Justin Felder resigned as one of the members of Board of Directors. Mr. Felder's resignation did not involve any disagreement with the company or other management relating to the company's operations, policies, practices or otherwise.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIEI:US $0.01 USD 0.00

BIEI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIEI.
View Industry Companies

Industry Analysis


Industry Average

Valuation BIEI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PREMIER BIOMEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at